The company hopes to improve its share price with ADAPT technology successes.
Big Picture – A Deep Dive Examination of Admedus Ltd
Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.
Admedus Ltd (ASX:AHZ) chief executive Wayne Paterson updates Proactive Investors on product development, a major agreement, key executive appointments, and strategic financing decisions. The global medical technologies company recently completed a $6 million capital raise. "On what is our strategy to move that share...
Wayne Paterson, chief executive of Admedus Ltd (ASX:AHZ), speaks about flagship ADAPT tissue products securing regulatory approval in Canada and a distribution network in the U.S.. Paterson also details landmark progress for the Admedus transcatheter aortic valve replacement (TAVR) device prototype. “The key for...
Wayne Paterson, chief executive of Admedus Ltd (ASX:AHZ), spoke to Proactive's Andrew Scott following the release of their quarterly update. It's a big week for Admedus with the launch of both CardioCel in India and CardioCel 3D in North America. CardioCel is the company’s flagship product and is becoming a...
Wayne Paterson, chief executive officer for Admedus, speaks with Proactive Investors.
Admedus Ltd's (ASX:AHZ) chief operating officer Julian Chick talks to Proactive Investors on the interim Herpes Simplex Virus Phase II clinical trial data. The blinded trial provided data from the first 20 patients to receive at least three vaccinations in the randomised, placebo–controlled HSV-2 vaccine Phase II...
Admedus Ltd (ASX:AHZ) is a leading diversified healthcare group.